Prim-O-glucosylcimifugin

Prim-O-glucosylcimifugin exerts anti-inflammatory effects through the inhibition of iNOS and COX-2 expression by through regulating JAK2/STAT3 signaling.

Product Specifications

CAS Number

[80681-45-4]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

COX; NO Synthase; TNF Receptor

Type

Natural Products

Related Pathways

Apoptosis; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Prim-O-glucosylcimifugin.html

Purity

99.87

Solubility

DMSO : ≥ 150 mg/mL

Smiles

COC1=C(C[C@@H](C(C)(O)C)O2)C2=CC(OC(CO[C@@H]([C@@H]([C@@H](O)[C@@H]3O)O)O[C@@H]3CO)=C4)=C1C4=O

Molecular Formula

C22H28O11

Molecular Weight

468.45

Precautions

H302, H315, H319, H335

References & Citations

[1]Zhou J, et al. Prim-O-glucosylcimifugin Attenuates Lipopolysaccharideinduced Inflammatory Response in RAW 264.7 Macrophages. Pharmacogn Mag. 2017 Jul-Sep;13 (51) :378-384.|[2]Chen N, et al. Prime-O-glucosylcimifugin attenuates lipopolysaccharide-induced acute lung injury in mice. Int Immunopharmacol. 2013 Jun;16 (2) :139-47.